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Abstract
Most rheumatic autoimmune diseases are complex in terms of their genetic origins and underlying
pathogenic processes. Non-hypothesis-driven scanning platforms are adding novel insights to our
understanding of these multifactorial diseases. This review summarizes the handful of recent
proteomic studies that have been executed using samples from patients with rheumatoid arthritis,
systemic lupus erythematosus, ankylosing spondylitis, osteoarthritis, or Sjogren’s syndrome. The
candidate biomarkers that have been uncovered in the reviewed studies have potential applications in
diagnosis, prognosis, and theranostics. Though we are at the infancy of the proteomics era in
rheumatology, the limited number of molecules uncovered thus far already hold promise. Ongoing
research in proteomics holds tremendous potential for shaping how rheumatic diseases are
diagnosed, prognosticated, and managed clinically over the coming years.
Introduction and context
Most rheumatic autoimmune diseases are complex in
terms of their genetic origins and underlying pathogenic
processes. Non-hypothesis-driven scanning platforms
are adding novel insights to our understanding of these
multi-factorial diseases. Transcriptomic profiling using
DNA microarrays has been applied to the study of almost
all rheumatic diseases. However, it is well accepted that
encoded proteins (rather than mRNA) may better reflect
cell function and disease. To date, only a handful of
studies have examined rheumatic diseases through the
prism of proteomics despite this approach emerging as
one of the most powerful tools in biomarker discovery.
Proteomic approaches include gel-based methods such
as two-dimensional difference gel electrophoresis (2D
DIGE) and modern mass spectrometric techniques. Since
most biological samples in rheumatic diseases are body
fluids and tissues that consist of complex mixtures of
proteins, a combination of both classical and modern
proteomic platforms are necessary for biomarker dis-
covery and to identify specific post-translational mod-
ifications [1]. The studies utilizing these techniques that
have discovered differentially expressed proteins
associated with several rheumatic diseases constitute
the focus of this review.
Recent advances
Severalstudieshaverecentlyidentifiedseveralproteinsthat
are differentially expressed in various rheumatic diseases.
The studies listed in Table 1 were selected because they
were all (a) unbiased proteomic profiling studies that were
conducted using tissue isolated from human rheumatic
diseases and uncovered (without any deliberate stimula-
tion) oneor moreproteinsasbeing differentially expressed
in the disease state, and (b) studies where the protein
identities were actually listed (as opposed toa series of m/z
values without actual protein identification). Excluded
from Table 1 were proteomic studies carried out in cells
stimulated in vitro and proteins that were not significantly
altered in the particular rheumatic disease under
investigation.
Rheumatoid arthritis
Thus far, eleven protein profiling studies have been
conducted in rheumatoid arthritis (RA) and related
diseases. Six have focused on serum and plasma while
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synovium. Using high-throughput mass spectrometric
techniques, these studies have uncovered approximately
33differentproteinsthataredifferentiallyexpressedinRA,
of which four have been independently confirmed by
other investigators (Table 1). Of particular interest are the
elevations in SAA (serum amyloid A) [2-5], SOD (super-
oxide dismutase) and TPI (triose phosphate isomerase)
[6,7] because they have been reported in multiple studies
in plasma and synovial tissue, as is evident from Table 1.
In addition to uncovering potential disease biomarkers,
proteomics can also yield insights into the molecular
pathways impacted by therapy. A recent example is the
identification of the nuclear factor-kappa B pathway as
being differentially expressed in RA patients treated with
anti-tumor necrosis factor-alpha (anti-TNFa)[ 8 ] .H e n c e ,
the observed changes in various inflammatory, anti-
inflammatory, and antioxidant proteins not only yield
clues regarding the pathogenesis of this disease but may
also aid clinicians in gauging disease prognosis and
monitoring response to treatment.
Osteoarthritis
A total of five different proteomic studies have been
conducted in osteoarthritis (OA). Of these studies, two
have focused on articular cartilage while three have
examined articular chondrocytes. Even though these
studies used gel electrophoresis for resolving the proteins,
Table 1. Protein markers in rheumatic diseases identified using proteomics
Rheumatic
disease




Serum [2,21,22] AAT, CRP, GAPDH, SAA, S100 proteins,
serotransferrin, TTR
AAT [23], CRP, SAA [3,4], S100 proteins
Plasma [3,4,19] Actin, apolipoprotein, calgranulin A, B, and C,
CRP, COLT1, SAA, SAA1, talin 1, thymosin
b4, PF4
Apolipoprotein, COLT1, SAA [2,3,5], PF4
Synovial fluid and tissue
[5,6,21,23,24]
Aldolase A, annexin, calcium-binding S100
proteins, calgranulin A (MRP8), cathepsin D,
CRP, ENOA, Ig k-chain, MnSOD, NGAL,
PRDX2, PRDX4, SOD2, TERA, TG2, TPI,
TXNDC5
Aldolase A [25], annexin, calcium-binding S100
proteins, calgranulin A (MRP8), cathepsin D, CRP
[26], ENOA, Ig k-chain, MnSOD, NGAL, PRDX2,
PRDX4, SOD2, TPI, TXNDC5
Whole saliva [27] 6-PGDH, 14-3-3 protein, apolipoprotein A,
calgranulin A and B, E-FABP, GRP78/BiP,
PRDX5
6-PGDH, 14-3-3 protein, apolipoprotein A, calgra-
nulin A and B, E-FABP, GRP78/BiP, PRDX5
Osteoarthritis Articular tissue [28],
cartilage [29], and
chondrocytes [18,30,31]
ADH, ADK1, ANNX-1, COLL-I and -VI,
ENOA, FR, Hsp 27, HtrA1, KPYM, PEBP, PRDX3,
RNF149, ROS, SOD2, SODM, TRAP1, TUB,
vimentin, Zn-RF
ANNX-1, COLL-I and VI [11], Hsp 27, HtrA1 [9,10],
ROS, SOD2, TRAP1, vimentin [12]
Ankylosing
spondylitis
Serum [32] Haptoglobin precursor Haptoglobin precursor




Urine [14,15] Hepcidin-20 and -25, PGD2, renin, SAP, SOD,
total protease




Saliva [35-37] a-amylase, a-defensin, amylase precursor, b-actin,
calgranulin A and B, carbonic anhydrase, cystatin
precursor, FABP, GSH, IgG receptor, keratin,
LEI, PIP, serum albumin, vitamin D
a-amylase, a-defensin [17], b-actin, calgranulin A and
B [38], carbonic anhydrase [39], cystatin precursor,
keratin [37]
Salivary gland [17] a-defensin, calmodulin a-defensin, calmodulin
Listed in the third column of Table 1 are all proteins that were upregulated (in bold font) or downregulated (in regular font) in disease samples compared
with healthy controls (or disease control), as listed in the original reports. The criteria used to decide whether or not a study was included in Table 1 are
detailed in the text. The differentially expressed proteins that have been validated using orthogonal approaches and/or in independent studies are listed in
the final column. 6-PGDH, 6-phosophogluconate dehydrogenase; AAT, alpha 1-antitrypsin; ADH, alcohol dehydrogenase; ADK1, adenylate kinase
isoenzyme 1; ANNX-1, annexin-1; COLL-I, collagen type I; COLT1, coactosin-like 1; CRP, C-reactive protein; E-FABP, epidermal fatty-acid binding protein;
ENOA, alpha enolase; FABP, fatty-acid binding protein; FR, flavin reductase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GRP78/BiP, 78-kDa
glucose-regulated protein precursor (also known as binding immunoglobulin protein); GSH, glutathione; Ig k-chain, immunoglobulin kappa chain; IgG
receptor, immunoglobin G receptor; KPYM, pyruvate kinase isozymes M1/M2; LEI, leukocyte elastase inhibitor; MnSOD, manganese superoxide dismutase;
MRP8, myloid-related protein 8; NGAL, neutrophil gelatinase-associated lipocalin; PA28, protein activator of the 20 S proteasome; PBMC, peripheral blood
mononuclear cell; PEBP, phosphatidylethanolamine-binding protein; PF4, platelet factor 4; PGD2, prostaglandin D2; PIP, prolactin-inducible protein; PRDX2,
peroxiredoxin-2; RNF149, RING finger protein 149; ROS, reactive oxygen species; SAA, serum amyloid A; SAP, serum amyloid P component; SOD,
superoxide dismutase; SODM, mitochondrial superoxide dismutase, TERA, transitional endoplasmic reticulum ATPase; TG2, transglutaminase 2; TPI, triose
phosphate isomerase; TRAP1, tumor necrosis factor receptor-associated protein 1; TTR, transthyretin; TUB, Tubby protein homolog; TXNDC5,
thioredoxin domain-containing protein 5; Zn-RF, zinc RING finger protein.
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metric techniques have enabled the identification of
approximately 20 proteins as being differentially
expressed in OA (Table 1). Of these 20 proteins, the
elevations in HtrA1 [9,10], collagen [11], and vimentin
[12] were confirmed by independent studies (Table 1).
The upregulation of these molecules again sheds light on
the pathogenic cascades underlying this disease and
underscores the functional importance of physiological
processes aimed at maintaining sound articular structure
and function.
Ankylosing spondylitis
Only three proteomic studies have been conducted in
ankylosing spondylitis (AS) to date, of which two have
examined serum and plasma while the most recent study
was performed using peripheral blood mononuclear
cells. In addition to using advanced mass spectromet-
ric techniques, Gao and colleagues [13] employed a
metabolomic platform to identify approximately seven
different markers that were differentially expressed in AS.
Clearly, validation and independent confirmation of
these findings is warranted, and until further validation
and information becomes available, it is difficult to
conjecture the biological and clinical importance of the
identified molecules.
Systemic lupus erythematosus
Although serum and plasma samples from systemic
lupus erythematosus (SLE) patients have not been
systematically scanned, two groups have examined
urine from lupus nephritic subjects. One report found
that the urinary proteins overexpressed in lupus nephritis
include hepcidin [14], while the other reported an
association with SAP (serum amyloid P component),
PGD2 (prostaglandin D2), SOD, renin, and protease
[15]. Elevated urinary hepcidin and PGD2 have also
been confirmed by independent reports [16]. The
presence of these molecules in high amounts in SLE
patients indicates their potential role in either disease
progression (e.g., protease and SAP) or disease modula-
tion (e.g., SOD) in nephritis. Additionally, monitoring
the levels of these molecules may also help clinicians
predict the disease course of these devastating ailments.
Sjogren’s syndrome
Recently, four different proteomic studies have been
performed in Sjogren’s syndrome (SS). Three studied
saliva while one examined the salivary gland proteome
[17]. Collectively, 16 different proteins have been
identified in SS (of which seven have been indepen-
dently confirmed by multiple reports) and include
elevations in b-actin, a-defensin, keratin, calmodulin,
and calgranulin, as detailed in Table 1. A significant
increase in levels of these proteins may reflect underlying
acinar cell damage (e.g., keratin) and inflammation
(e.g., calmodulin and calgranulin) that may mediate the
pathogenesis of this disease.
A technology in evolution
Proteomic approaches are constantly expanding our
ability to quantify changes in protein expression and
modification in an unbiased fashion for a given biological
sample. Current limitations include our lack of ability to
extend comprehensive coverage to encompass the entire
proteome to include even the low-abundance proteins
with sufficient degrees of quantification and reproduci-
bility. Encouragingly, the technology used has been
steadily evolving over the past decade. For example, until
recently, 2D gel electrophoresis (2DGE) was the most
powerful proteomic profiling technique for both protein
identificationandquantitationinclinicalsamples.Butthis
platform fails to detect proteins with extreme pH values,
high and low molecular weights, proteins with low copy
numbers, and those with hydrophobic domains. How-
ever, recently, liquid chromatography-based mass spec-
trometric (LC-MS) techniques have begun to exercise their
dominance in the field, although they are more costly
and technologically intensive. Present day technologies
allow for more accurate quantitation of the differentially
expressed proteins. Additionally, quantification of pro-
teins in samples from different subjects, different stages of
disease, or different treatment conditions can be achieved
by using protein tags such as iTRAQ (isobaric tag for
relative and absolute quantitation), ICAT (isotope-coded
affinity tag) and cICAT (cleavable ICAT), which signifi-
cantly reduce sample-to-sample variation and time-point
variation. Although most of the shortcomings of 2DGE
can be alleviated, there is still room for improvement with
LC-MS-based platforms as the field marches towards
attaining total coverage of the entire proteome at an
affordable cost.
Implications for clinical practice
Candidate biomarkers identified using high-throughput
proteomic platforms have potential applications in
diagnosis, prognosis, and theranostics. Though we are in
the infancy of the proteomics era in rheumatology, the
limited number of molecules uncovered thus far already
hold promise. Some of these molecules yield insights into
the disease process. For example, in RA and OA, elevated
annexin 1 may serve to inhibit inflammatory cytokines
such as interleukin (IL)-1, TNFa, and IL-6 [7]. Over-
expression of annexin-1 in these disease settings may
indicate an increased ‘attempt’ to suppress inflammation.
Similarly the upregulation of MnSOD (manganese super-
oxide dismutase) and PRDX2 (peroxiredoxin 2) may
function to suppress oxidative stress, underscoring their
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cant upregulation of a-enolase and TPI in synovial
fibroblasts in RA and OA alludes to the potential
diagnostic and prognostic value of these two biomarkers
[7]. Along the same line, the elevated TNF receptor-
associated protein 1 (TRAP1) molecule in patients with
OA may also serve to protect cells from oxidative-stress-
induced apoptosis, since TRAP1 is a mitochondrial
protein belonging to the Hsp90 family of molecular
chaperones [18].
Some markers may have a role in predicting disease and
also in monitoring response to treatment. One example
of this in the field of lupus is hepcidin. In patients with
SLE, urinary hepcidin-20 has been reported to increase
4 months pre-flare and return to baseline at renal flare. In
the same study, hepcidin-25 was noted to decrease at
renal flare and return to baseline 4 months post-flare.
Since hepcidin-20 increases pre-flare, it has the potential
to be a biomarker for predicting impending renal failure.
Additionally, because hepcidin-25 levels were modu-
lated by treatment, it also has biomarker potential for
monitoring treatment response [14]. However, these
predictions need to be validated in independent patient
cohorts. In a more recent study, it was reported that
urinary protease in lupus nephritis was renal in origin
and correlated well with concurrent renal pathology
activity [15]. Clearly, this is a rapidly evolving field, and
the most predictive biomarkers for foreboding disease
flares and predicting treatment response await systematic
elucidation.
Arelatedclassofbiomarkersisthosethatcanpredictwhich
patients might respond best to a given therapeutic regime.
OneexampleofthisisevidentinthefieldofRA;itappears
that monitoring the levels of plasma apolipoprotein-1
may indicate which RA patients are likely to respond to
infliximabtreatment,whileassayingPF4(plateletfactor4)
levels may indicate which RA patients may not respond
[19]. Once again, this observation needs to be validated,
and the several additional markers reported in RA also
need to be tested for their theranostic potential. Extra-
polating from these early studies, the ongoing research in
proteomics holds tremendous potential for shaping how
rheumatic diseases are diagnosed, prognosticated, and
managed in a clinical setting in the coming years.
Looking to the future
Thusfar,therehasbeenadearthofquantitativeproteomic
studies in the field of rheumatology. As discussed above,
this is now being remedied through several novel
technologies. With the employment of more quantitative
proteomicplatforms,rheumatologistsarelikelytosucceed
in discovering an increasing panel of potential disease
markers with a greater degree of sensitivity. The challenge
at that point would be to validate the identified markers
using orthogonal platformsand to establish the specificity
of the molecule for the various rheumatic diseases. Being
able to predict the disease course and dictate the optimal
treatment regime simply by examining the patient’sf l u i d s
would transform how rheumatology is practiced.
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